OptimizeRx price target lowered to $18 from $32 at Roth Capital

Roth Capital lowered the firm’s price target on OptimizeRx (OPRX) to $18 from $32 and keeps a Buy rating on the shares after it’s below-consensus revenue guidance. Revenue weakness rapidly emerged as large pharma clients struggle with the Trump administration’s “most favored nation” pricing initiative launched in May of 2025, the analyst tells investors in a research note. The firm retains its Buy rating given the already severe valuation pressure on the stock, Roth adds.